Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

1-1-2014

A supplementary home dose of oral ondansetron given in
anticipation of recurrent emesis in paediatric acute gastroenteritis
Mark Xu
Schulich School of Medicine & Dentistry

Michael Rieder
Schulich School of Medicine & Dentistry, mrieder@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Xu, Mark and Rieder, Michael, "A supplementary home dose of oral ondansetron given in anticipation of
recurrent emesis in paediatric acute gastroenteritis" (2014). Paediatrics Publications. 1504.
https://ir.lib.uwo.ca/paedpub/1504

Therapeutic Dilemma

A supplementary home dose of oral ondansetron
given in anticipation of recurrent emesis in paediatric
acute gastroenteritis
Mark Xu HBSc, Michael Rieder MD PhD

Y

INTERVENTIONS

Acute gastroenteritis affects approximately 16 million children
<5 years of age annually in the United States and accounts for
roughly three million physician visits (1). The typical presentation
includes acute onset of fever, abdominal cramps, emesis and diarrhea (2). Viruses are the most common cause, although bacteria
and parasites are also implicated (3). In most cases, acute gastroenteritis is self-limited and does not require pharmacotherapy (4).
Increased morbidity typically results from dehydration and electrolyte imbalances (5). Oral rehydration therapy and correction of
electrolyte imbalances are the most important steps in management (5). In the United States, approximately 220,000 children
<5 years of age are hospitalized annually for treatment of dehydration (1), with comparable rates in Canada (6). Rotavirus, the most
common cause of severe gastroenteritis, is estimated to have a
societal cost of $1 billion annually (7). The development and
implementation of a rotavirus vaccine has reduced ED visit rates
and hospitalization significantly (8); however, acute gastroenteritis
remains a commonly encountered presentation in paediatric emergency departments, and carries a societal cost of up to $18.4 million annually in Canada (9).
Ondansetron is an antiemetic medication indicated for the
prevention of nausea and vomiting in patients undergoing chemotherapy, radiation therapy and surgery (10). When taken orally, it
is absorbed into the gastrointestinal tract and reaches maximum
plasma concentration after 1.5 h (11). Ondansetron is a serotonin
5-HT3 receptor antagonist and is believed to function by suppressing the vomiting centres in the brain and blocking afferent
depolarization of vagal nerves peripherally in the intestines (11).
While the exact mechanism of emesis is not known, it has been
proposed that the cause of emesis in acute gastroenteritis occurs
due to viral- or bacterial-induced damage to the intestinal mucosa
(12). This leads to the release of serotonin by gut enterochromaffin cells, which bind to the 5-HT3 receptors in the bowel to provoke an emetic response (12).
Ondansetron has gained popularity among paediatric ED physicians for the treatment of acute gastroenteritis (13). It is known to
be an effective antiemetic and is relatively safe, with the most common side effect being diarrhea, which is usually mild and self-limited

to 48 h (14,15). Two systematic reviews have concluded that ondansetron is effective in reducing persistent vomiting, the need for
intravenous fluids and the rate of hospitalization (15,16).
Additionally, the use of ondansetron appears to decrease ED length
of stay and ED revisit rate (17). In countries that use intravenous
fluids, the use of ondansetron leads to significant cost savings (18).
Alternative antiemetics including metoclopramide, trimethobenzamide and pyrilamine-pentobarbital have also been studied; however, these studies were of lower quality and reported inconsistent
results (15). The Canadian Paediatric Society currently recommends a single dose of oral ondansetron for the management of
patients six months to 12 years of age who present to the ED with
vomiting and dehydration due to suspected gastroenteritis, and
those failing oral rehydration therapy (ORT) (19). The use of
ondansetron in patients with predominantly diarrhea is not recommended (19). Ondansetron should also be avoided in patients with
congenital long QT syndrome due to the risk for Torsade de Pointes.
The Food and Drug Administration has recommended electrocardiographic monitoring in patients with electrolyte abnormalities
(ie, hypokalemia), congestive heart failure, bradyarrhythmias or
patients on other QT-prolonging medications (20).
While ondansetron is widely used as an adjunct in the treatment of acute gastroenteritis by paediatric ED physicians (13),
sparse literature exists on the utility of discharging patients with
an at-home oral dose of ondansetron to be used as prophylaxis for
recurrent emesis. The symptomatic period of acute gastroenteritis can exceed seven days (2). The terminal elimination half-life
of ondansetron is only approximately 2 h to 4 h (11). Presumably,
a proportion of patients who had taken ondansetron in the ED
and were asymptomatic at the time of discharge may develop
recurrent emesis at home. As a result, they may ultimately return
to the ED, leading to increased use of hospital resources. In
Canada, the point-of-care administration of ondansetron is estimated to cost $12.86 while an ED visit costs $229.93, not including intravenous catheter insertion ($84), possible hospitalization
($955) or travel expenses for patients ($21.59) (18). A recent
small study found that 24% of paediatric patients who were
treated with a single dose of ondansetron for acute gastroenteritis
in the ED reported experiencing recurrent emesis within 24 h of
discharge (21). Perhaps the use of a physician-dispensed, asneeded home dose of ondansetron given to patients in anticipation of recurrent emesis and risk of dehydration may prevent a
return to the ED. While a 2010 study found no change improvement in ED revisit rates after discharging patients home with a
written prescription for ondansetron, the authors caution that
they did not track the number of patients who actually filled
their prescriptions (22). A home dose of ondansetron given to
patients by the ED physician as part of discharge planning may
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ou are a physician working in a paediatric emergency department (ED) in a large urban hospital. A two-year-old boy presents with a recent history of fever, emesis and abdominal pain.
After examining him, you diagnose him with acute gastroenteritis
and give him a 2 mg oral dose of ondansetron. Thirty minutes
later, his symptoms have subsided and he is tolerating oral fluids.
His parents ask you if they can go home with a ‘back-up’ dose of
ondansetron in case his symptoms recur. What do you do?

Therapeutic Dilemma
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summary

Ondansetron is a useful adjunct for the treatment of acute gastroenteritis in the paediatric ED. The use of ondansetron is associated
with many benefits including decreased emesis, decreased need for
intravenous fluids, decreased rate of admission, decreased length of
stay, decreased revisit rates and increased cost savings (15-18).
There may be value in giving patients a second as-needed home
dose of ondansetron as part of ED discharge planning, with the
appropriate patient education, in anticipation of recurrent emesis.
This practice may further reduce ED revisit rates and also prevent
morbidity and hospitalization associated with severe dehydration
for patients who do eventually return to the ED, especially those in
rural communities where timely treatment and access to an ED is
difficult. The decision to dispense ondansetron should be made
clinically by the ED physician for patients who have failed ORT
whose symptoms are predominantly emesis as opposed to diarrhea,
and when the discharging physician is reasonably certain of a diagnosis of acute gastroenteritis and not something more sinister.
There is currently no consensus on the role of ED-provided
ondansetron for out-of-hospital use for paediatric patients with
acute gastroenteritis. Future studies are needed to determine the
potential impact on morbidity and the health care economy.
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promote compliance of using ondansetron on an outpatient basis
(21). Moreover, it may serve to reassure some parents who may
be otherwise uncomfortable in taking their children home. It
needs to be emphasized that ORT remains the cornerstone of
therapy for acute gastroenteritis, and parents need to be educated
to recognize the signs and symptoms of dehydration and to only
administer ondansetron if ORT fails due to recurrent emesis.
This may be accomplished through teaching by the discharging
physician (or an ED nurse) and an information sheet for
parents.
A commonly cited reason against prescribing ondansetron for
home use is fear of masking other diseases not identified at the
initial visit (21). Due to this caution, many physicians use ondansetron in the ED but hesitate to prescribe it for home use (21). A
recent small study involving paediatric patients with acute gastroenteritis found that a single dose of ondansetron given at home
does not appear to increase the rate of alternative diagnoses (21).
Additional studies are needed to more clearly delineate the relationship between the home use of ondansetron and the potential
masking of other conditions with a similar presentation. Until
then, we caution against dispensing more than one additional dose
of ondansetron.

